Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: Possible role for aldose-reductase inhibition

Transplantation

Volumn 84, Issue 6, 2007, Pages 755-762

  Gottmann, Uwe ^a   Brinkkoetter, Paul T ^a   Hoeger, Simone ^a   Gutermann, Katrin ^a   Coutinho, Zora Martins ^a   Ruf, Tobias ^a   Hui, Song ^a   Liu, Zhenzi ^a   Schnuelle, Peter ^a   Van Der Woude, Fokko J ^a   Braun, Claude ^b   Yard, Benito A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Ischemia reperfusion; Kidney; Rat; Statin; Transplantation

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ATORVASTATIN; EPALRESTAT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HISTOPATHOLOGY; ISCHEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; NEPHRITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ALDEHYDE REDUCTASE; ANIMALS; GENE EXPRESSION PROFILING; GRAFT SURVIVAL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; PYRROLES; RATS; RATS, INBRED STRAINS; REPERFUSION INJURY;

EID: 34748839568     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000281410.85659.48     Document Type: Article

References (42)

1. Cole E, Naimark D, Aprile M, et al. An analysis of predictors of long-term cadaveric renal allograft survival. Clin Transplant 1995; 9: 282.
2. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 2004; 65: 713.
3. Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74: 1156.
4. Chiang-Ting C, Tzu-Ching C, Ching-Yi T, et al. Adenovirus-mediated bcl-2 gene transfer inhibits renal ischemia/reperfusion induced tubular oxidative stress and apoptosis. Am J Transplant 2005; 5: 1194.
5. Nakao A, Neto JS, Kanno S, et al. Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant 2005; 5: 282.
6. Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67: 1753.
7. Huang H, He Z, Roberts LJ 2nd, Salahudeen AK. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. Am J Transplant 2003; 3: 1531.
8. Gueler F, Rong S, Park JK, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13: 2288.
9. Knoll T, Schult S, Birck R, et al. Therapeutic administration of an endothelin-A receptor antagonist after acute ischemic renal failure dose-dependently improves recovery of renal function. J Cardiovasc Pharmacol 2001; 37: 483.
10. Braun C, Vetter S, Conzelmann T, et al. Improved recovery following posttransplant acute renal failure in rat renal isografts with an oral endothelin-A receptor antagonist. Exp Nephrol 2000; 8: 283.
11. Gottmann U, Brinkkoetter PT, Bechtler M, et al. Effect of pre-treatment with catecholamines on cold preservation and ischemia/reperfusion-injury in rats. Kidney Int 2006; 70: 321.
12. Gottmann U, Notheisen A, Brinkkoetter PT, et al. Influence of donor pretreatment with dopamine on allogeneic kidney transplantation after prolonged cold storage in rats. Transplantation 2005; 79: 1344.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349.
15. Mach F. Statins as immunomodulatory agents. Circulation 2004; 109(21 Suppl 1): II15.
16. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399.
17. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469.
18. Ji P, Si MS, Podnos Y, et al. Prevention of chronic rejection by pravastatin in a rat kidney transplant model. Transplantation 2002; 74: 821.
19. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361): 2024.
20. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66: 1549.
21. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 2001; 101: 79.
22. Yokota N, O'Donnell M, Daniels F, et al. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 2003; 23: 13.
23. Sabbatini M, Pisani A, Uccello F, et al. Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol 2004; 15: 901.
24. Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury. Faseb J 2004; 18: 1192.
25. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997; 46: 292.
26. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents. Circulation 2004; 109(21 Suppl 1): II18.
27. Petrash JM. All in the family: aldose reductase and closely related aldoketo reductases. Cell Mol Life Sci 2004; 61: 737.
28. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol 1998; 275: H195.
29. Hwang YC, Sato S, Tsai JY, et al. Aldose reductase activation is a key component of myocardial response to ischemia. Faseb J 2002; 16: 243.
30. Hwang YC, Bakr S, Ellery CA, et al. Sorbitol dehydrogenase: A novel target for adjunctive protection of ischemic myocardium. Faseb J 2003; 17: 2331.
31. Amano S, Yamagishi S, Kato N, et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 2002; 299: 183.
32. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003; 14: S233.
33. Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. Faseb J 2002; 16: 123.
34. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. Faseb J 1999; 13: 23.
35. Ho HT, Chung SK, Law JW, et al. Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol 2000; 20: 5840.
36. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: Etiology, management and long-term significance. J Urol 1996; 155: 1831.
37. McLaren AJ, Jassem W, Gray DW, et al. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999; 13: 266.
38. Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59: 565.
39. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991.
40. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA. The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984; 38: 643.
41. Marcen R, Orofino L, Pascual J, et al. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 1998; 66: 461.
42. Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8: 101.